To include your compound in the COVID-19 Resource Center, submit it here.

Intercept details safety initiatives for Ocaliva, reiterates NASH plans

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) announced its plans Monday to address an FDA drug safety communication issued last Thursday regarding the company’s primary biliary cholangitis (PBC) drug Ocaliva obeticholic acid. The company also reiterated its Phase

Read the full 356 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE